Sickle Cell Disease (SCD)

FDA Approves Groundbreaking Cell-Based Gene Therapies for Sickle Cell Disease

Stacy M. Brown NNPA Newswire Senior National CorrespondentDecember 14, 2023

The U.S. Food and Drug Administration (FDA) has greenlit two revolutionary cell-based gene therapies, Casgevy and Lyfgenia, marking a significant leap forward in treating sickle cell disease (SCD) for patients aged 12 and older.

Dr. Ben Chavis

OP-ED: Black Americans and COVID-19 Clinical Trials

Dr. Benjamin F. Chavis, Jr., President and CEO, National Newspaper Publishers AssociationSeptember 10, 2020

Black Americans have to be involved at all levels of responding to the COVID-19 pandemic. We cannot afford to be silent, detached, denied, or prevented from being at the decision-making tables in terms of COVID-19 public health policies, research, clinical trials, remedies, and vaccine development. Our lives and future are at stake.